DNTH - Company ID 0001690585
The table below shows Dianthus Therapeutics, Inc. /DE/'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$28.86M | -$27.63M | -$14.94M | -$10.28M | -$19.74M | -$16.77M |
| Capital expenditure | - | - | - | $245.00K | $27.00K | $7.00K |
| Investing cash flow | -$133.97M | $14.79M | -$5.51M | $18.13M | -$40.14M | $7.49M |
| Dividends paid | - | - | - | - |
Dianthus Therapeutics, Inc. /DE/ reported operating cash flow of -$129.06M for fiscal year 2025. That is down 65.1% from -$78.18M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$6.53M (FY 2016) to -$129.06M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $739.41M | $161.00K | $217.85M | $0.00 | $0.00 | $418.00K |